Novel Methods for Secure, Non-invasive Drugs of Abuse Testing.
A study team at the University of Surrey are trying to develop a fast and effective way of testing for drugs of abuse using fingerprints. Current methods such as urine or blood sampling are invasive, not easily obtained and require costly waste disposal services. Therefore, a quicker and more cost effective method would be highly beneficial to the NHS. Fingerprint testing could revolutionise the way drug and alcohol services test for drugs of abuse as it would be easier for both clinicians and patients.
The study is recruiting female and male drug users, aged between 18 and 65 years old, who are currently enrolled on a drug detoxification program. The study is recruiting users of cocaine, benzodiazepine, opiate, cannabis and amphetamine.
Researchers from the University of Surrey will ask you to print all of your fingers individually onto slides. They would also like to obtain an oral swab sample and a urine sample. Participants will receive a £5 voucher for each sample type they donate - £15 in total. Participants can give samples at multiple visits if they wish to. On occasion, the researchers may ask for a blood sample instead of the oral swab or urine sample. Blood will be obtained by a trained member of staff. All samples will be anonymised and none will be used for identification purposes. All sample collection will take place within the clinic so you will not have to attend any extra appointments. After you have given your samples, nothing else will be required of you. However if you decide that you do not want to take part in the study, you can contact the study team any time and your samples will be removed.
If you are attending the Tuesday clinic from 8:30am to 12pm at Windmill House, the study team will be available to discuss the study or you can ask a member of the care team.
Alternatively please contact Sarah Hamilton on 019327 222 47/ 0746 871 6044 or Sarah.Hamilton@sabp.nhs.uk .
Genetic Case Control and Brain Imaging Studies of Mental Illness and Dementia. This is shortened to DNA Polymorphisms in Mental Illness (DPIM).
The research is looking into the genetics of Bipolar Disorder, Schizophrenia and Alcoholism. The aim of our study is pave the way for new treatments and preventative strategies. These may be more personalised and also associated with fewer or absent side effects. We do this by using participant DNA samples to look for mutations in specific genes. If a mutation is found, we can then analyse how that might influence the function of the protein it codes for. For example, we have been looking at Ankyrin-3 (a gene which codes for Ankyrin-G protein). Ankyrin-G is known to modulate the influence of Lamotrigine on sodium channels. Through this research, it may be possible, in the future, to modify the effect of Lamotrigine when it is prescribed by clinicians for patients. We are not aiming to develop predictive tests for Bipolar Disorder, but we are trying to minimise (or potentially eliminate) side effects of mood stabilising drugs.
Participants and normal controls for schizophrenia, bipolar disorder, alcoholism and autism must be of white/Caucasian English, Irish, Scottish or Welsh extraction and have both parents and all four grandparents of English, Irish, Welsh or Scottish ethnicity, with the exception that one grandparent who may be of white European Caucasian origin, but not Jewish. The Ancestry Check List is used to record this information.
Normal control volunteers must have no personal or family history of mental illness such as anxiety neurosis, autism, schizophrenia, bipolar disorder, depression, unipolar affective disorder, alcoholism, Giles de la Tourette Syndrome or Alzheimer’s dementia. Both parents and all four grand-parents must be of Caucasian English, Irish, Welsh or Scottish ancestry. They should be excluded if there is mental illness of any type in the 1st degree relatives of normal control volunteers. .
All you would have to do is a one-off interview and have a blood sample
If you are interested in taking part or would like some more information please contact Jane Gregg, Clinical Research Coordinator, on 019327 222 47 or email@example.com . Alternatively you can contact the Trust’s Principal Investigator for the study Dr. Ramin Nilforooshan, Ramin.Nilforooshan@sabp.nhs.uk .